AVLN · Avalyn Pharma Inc.
$39.25
+2.67 (+7.30%)
At close · Aug 14
Market Cap
$1.74B
Shares
44.33M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$39.25
Open$36.80
Day$35.07–39.48
Available close range$25.68–39.25
Avg vol 30d237K
Short int2.0M · 4.6% float · 9.4d
Short vol63%
Last earningsJun 3, 2026
DataApr 2026–Aug 2026
Filing10-Q · Aug 12
The closing range uses available history since Apr 30, 2026; less than a full year is stored.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Limited
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
+31%
above
RSI (14)
76
overbought
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+92 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.55% of float · ▼ -7.8% MoM · 9.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
92 holders — 13F breadth
Squeeze score
68
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
69%
annualized · 1-yr
Max drawdown
−22%
past year
ATR
6.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
+31%
Bullish
RSI (14)
76
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+92 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.55% of float · ▼ -7.8% MoM · 9.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
92 holders — 13F breadth
Price context
position in its available closing range
Range low $26
Now $39 · 100%
Range high $39
vs 50-day avg +31%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, and marketable securities | $413.5M | the second quarter of 2026 | — |
|
|
|||
| MIST global Phase 2b trial enrollment | 398 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AVLN
this stock
Avalyn Pharma Inc.
|
$1.74B | — | — | — | 4.6% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AVLN | +15.7% | +38.7% | — | +36.3% | — |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +15.3% | +34.2% | — | +32.4% | — |
Key facts
CIK
1540171
CUSIP
05348Y105
13F (30d)
95 filings
93 filers
Visit website
Investor relations